Enhancement of Intestinal Barrier Function and Alleviation of Mycophenolic Acid Toxicity by a Probiotic-Conditioned Medium in Vitro

Why It Matters

A postbiotic approach can protect the gut barrier in immunocompromised patients on MPA/MMF, reducing gastrointestinal side effects while avoiding infection risks associated with live probiotics.

Key Takeaways

• Probiotic‑conditioned medium raises TEER, indicating tighter intestinal barrier
• ZO‑1 and claudin‑5 protein levels increase even with MPA/MMF present
• ROS generation from immunosuppressants is markedly reduced by the postbiotic
• Cell viability improves; PP reverses MPA/MMF‑induced cytotoxicity
• ABCB1 pump activity drops, yet drug crossing the barrier remains unchanged

Pulse Analysis

Immunosuppressive regimens that include mycophenolic acid (MPA) or its pro‑drug mycophenolate mofetil (MMF) are cornerstone therapies for organ‑transplant recipients, yet they frequently provoke gastrointestinal toxicity by disrupting the intestinal barrier. The barrier’s integrity relies on tight‑junction proteins, a balanced microbiome, and controlled oxidative stress. Conventional probiotic supplementation has shown promise, but live microorganisms pose infection concerns for patients with suppressed immunity, prompting interest in postbiotic solutions that deliver microbial metabolites without viable cells.

In the recent in‑vitro investigation, researchers cultured a multistrain probiotic blend, filtered out the bacteria, and applied the resulting conditioned medium to differentiated CaCo‑2 monolayers. Within six hours, the postbiotic elevated transepithelial electrical resistance, a direct indicator of barrier tightness, and boosted expression of ZO‑1 and claudin‑5, key proteins that seal intercellular gaps. Simultaneously, the medium quenched reactive oxygen species generated by MPA, MMF, or the oxidative agent tBHP, thereby preserving cellular viability. Notably, the conditioned medium reduced activity of the efflux transporter ABCB1, yet this did not increase drug passage across the epithelium, suggesting that barrier protection operates independently of drug absorption dynamics.

These findings have practical implications for transplant care. A postbiotic formulation could be administered alongside immunosuppressants to pre‑condition the gut epithelium, diminishing the incidence of diarrhea, malabsorption, and systemic inflammation without the risk of probiotic‑related sepsis. Future clinical trials should evaluate dosing, formulation stability, and long‑term outcomes, while pharmaceutical developers may explore scalable production of probiotic‑conditioned media as a novel adjunct therapy in the transplant market.